287 related articles for article (PubMed ID: 24705787)
1. Expression of RAGE and HMGB1 in thymic epithelial tumors, thymic hyperplasia and regular thymic morphology.
Moser B; Janik S; Schiefer AI; Müllauer L; Bekos C; Scharrer A; Mildner M; Rényi-Vámos F; Klepetko W; Ankersmit HJ
PLoS One; 2014; 9(4):e94118. PubMed ID: 24705787
[TBL] [Abstract][Full Text] [Related]
2. Expression of receptor for advanced glycation end-products (RAGE) in thymus from myasthenia patients.
Bouchikh M; Zouaidia F; Benhaddou EHA; Mahassini N; Achir A; El Malki HO
Rev Neurol (Paris); 2017 Jun; 173(6):388-395. PubMed ID: 28461027
[TBL] [Abstract][Full Text] [Related]
3. Increased number of Hassall's corpuscles in myasthenia gravis patients with thymic hyperplasia.
Matsui N; Ohigashi I; Tanaka K; Sakata M; Furukawa T; Nakagawa Y; Kondo K; Kitagawa T; Yamashita S; Nomura Y; Takahama Y; Kaji R
J Neuroimmunol; 2014 Apr; 269(1-2):56-61. PubMed ID: 24556356
[TBL] [Abstract][Full Text] [Related]
4. Analysis of TNF-related apoptosis-inducing ligand and receptors and implications in thymus biology and myasthenia gravis.
Kanatli I; Akkaya B; Uysal H; Kahraman S; Sanlioglu AD
Neuromuscul Disord; 2017 Feb; 27(2):128-135. PubMed ID: 28012741
[TBL] [Abstract][Full Text] [Related]
5. Pathological Findings in Myasthenia Gravis Patients with Thymic Hyperplasia and Thymoma.
Chen P; Wang YP; Mou DL; Li ZY; Qu QM; Wang HY; Deng Y; Li XF; Wang T; Xu XH; Zhao G
Pathol Oncol Res; 2018 Jan; 24(1):67-74. PubMed ID: 28299711
[TBL] [Abstract][Full Text] [Related]
6. PD-1 and PD-L1 expression in thymic epithelial tumours and non-neoplastic thymus.
Bagir EK; Acikalin A; Avci A; Gumurdulu D; Paydas S
J Clin Pathol; 2018 Jul; 71(7):637-641. PubMed ID: 29439008
[TBL] [Abstract][Full Text] [Related]
7. Primary cultures of human myasthenia gravis thymus and normal thymus. Studies of cell morphology, cell proliferative pattern and localization of alpha-bungarotoxin binding sites on cultured thymic cells.
Matsumoto Y; Furuya A; Kobayashi T; Tsukagoshi H
J Neurol Sci; 1986 Sep; 75(2):121-33. PubMed ID: 3760907
[TBL] [Abstract][Full Text] [Related]
8. Immunocytochemical localization of thymosin-alpha 1 in thymic epithelial cells of normal and myasthenia gravis patients and in thymic cultures.
Dalakas MC; Engel WK; McClure JE; Goldstein AL; Askanas V
J Neurol Sci; 1981 May; 50(2):239-47. PubMed ID: 7014787
[TBL] [Abstract][Full Text] [Related]
9. Myoid cells and neuroendocrine markers in myasthenic thymuses.
Zółtowska A; Pawełczyk T; Stopa M; Skokowski J; Stepiński J; Roszkiewicz A; Nyka W
Arch Immunol Ther Exp (Warsz); 1998; 46(4):253-7. PubMed ID: 9779292
[TBL] [Abstract][Full Text] [Related]
10. [Immunohistochemical study of 11 epithelial tumors of the thymus or thymomas with anti-keratin antibodies: KL-1].
Caillaud JM; Carlu C; Bretel JJ; Arriagada R
Rev Mal Respir; 1988; 5(2):153-7. PubMed ID: 2455924
[TBL] [Abstract][Full Text] [Related]
11. Glut-1 intensity and pattern of expression in thymic epithelial tumors are predictive of WHO subtypes.
Thomas de Montpréville V; Quilhot P; Chalabreysse L; De Muret A; Hofman V; Lantuéjoul S; Parrens M; Payan MJ; Rouquette I; Secq V; Girard N; Besse B; Marx A; Molina TJ
Pathol Res Pract; 2015 Dec; 211(12):996-1002. PubMed ID: 26534878
[TBL] [Abstract][Full Text] [Related]
12. The receptor for advanced glycation endproducts and its ligands in patients with myasthenia gravis.
Moser B; Bekos C; Zimprich F; Nickl S; Klepetko W; Ankersmit J
Biochem Biophys Res Commun; 2012 Mar; 420(1):96-101. PubMed ID: 22405771
[TBL] [Abstract][Full Text] [Related]
13. Nonneoplastic and nonhyperplastic thymus in myasthenia gravis. An immunohistochemical study with double immunoenzymatic labeling of basement membrane and cellular components.
Eimoto T; Kusano T; Ando K; Kikuchi M; Shirakusa T; Kawanami S
Am J Clin Pathol; 1990 Jul; 94(1):36-43. PubMed ID: 2193507
[TBL] [Abstract][Full Text] [Related]
14. PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus.
Marchevsky AM; Walts AE
Hum Pathol; 2017 Feb; 60():16-23. PubMed ID: 27746267
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the malignant grade of thymoma by morphometric analysis.
Nomori H; Horinouchi H; Kaseda S; Ishihara T; Torikata C
Cancer; 1988 Mar; 61(5):982-8. PubMed ID: 3338061
[TBL] [Abstract][Full Text] [Related]
16. Expression of NGF receptors in normal and pathological human thymus.
Parrens M; Labouyrie E; Groppi A; Dubus P; Carles D; Velly JF; de Mascarel A; Merlio JP
J Neuroimmunol; 1998 May; 85(1):11-21. PubMed ID: 9626993
[TBL] [Abstract][Full Text] [Related]
17. In vitro interleukin-1 (IL-1) production in thymic hyperplasia and thymoma from patients with myasthenia gravis.
Aime C; Cohen-Kaminsky S; Berrih-Aknin S
J Clin Immunol; 1991 Sep; 11(5):268-78. PubMed ID: 1795043
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis of myasthenia gravis. Acetylcholine receptor-related antigenic determinants in tumor-free thymuses and thymic epithelial tumors.
Kirchner T; Tzartos S; Hoppe F; Schalke B; Wekerle H; Müller-Hermelink HK
Am J Pathol; 1988 Feb; 130(2):268-80. PubMed ID: 2449082
[TBL] [Abstract][Full Text] [Related]
19. Activation of STAT3 in thymic epithelial tumours correlates with tumour type and clinical behaviour.
Chang KC; Wu MH; Jones D; Chen FF; Tseng YL
J Pathol; 2006 Oct; 210(2):224-33. PubMed ID: 16917804
[TBL] [Abstract][Full Text] [Related]
20. Corpuscular thymoma: entity or variant of organotypical thymomas WHO B2/B3?
Laeng RH; Eimoto T; Kuo TT; Zettl A; Marx A; Moschopulos M; Tateyama H; Shimokawa K
Pathol Res Pract; 2006; 202(10):697-704. PubMed ID: 16887284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
